ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations

SAN DIEGO—(BUSINESS WIRE)—May 2, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced that Elena Ridloff, CFA, has been appointedto the newly created position of Senior Vice President, InvestorRelations, leading investor and financial communications activities. Shewill report to Steve Davis, ACADIA’s President and Chief ExecutiveOfficer and serve as a member of the company’s Executive ManagementCommittee.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20180502005581/en/

Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)

“We are thrilled to welcome Elena Ridloff to our senior leadershipteam,” said Mr. Davis. “Elena’s deep knowledge of the healthcareindustry, strong relationships with the financial community, and keenunderstanding of capital markets make her a valuable addition to theteam as we continue to advance our development and commercial effortsfocused on CNS disorders with high unmet needs.”

Ms. Ridloff joins ACADIA from Alexion Pharmaceuticals, where she wasVice President, Investor Relations reporting to the Chief FinancialOfficer and serving as a member of the Operating Committee. In buildingand leading the investor relations function at Alexion, she played a keyrole in developing and executing the company’s investor relationsstrategy and outreach to broaden and strengthen the shareholder base.Prior to Alexion, she was Chief Executive Officer and Managing Member ofBIOVISIO, an independent consulting firm providing strategic, financialand investor relations counsel to the life sciences industry. Ms.Ridloff was also a Managing Director at Maverick Capital, a hedge fundbased in New York, and was responsible for investments in thebiotechnology, pharmaceutical, medical device and life science sectors.

Ms. Ridloff attended the University of Pennsylvania where she earned aBachelor of Arts in History and Sociology of Science. She is also a CFA^® charterholder.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the advancement of ACADIA’sdevelopment and commercial efforts. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drugdiscovery, development, approval and commercialization, and the factthat past results of clinical trials may not be indicative of futuretrial results. For a discussion of these and other factors, please referto ACADIA’s annual report on Form 10-K for the year ended December 31,2017 as well as ACADIA’s subsequent filings with the Securities andExchange Commission. You are cautioned not to place undue reliance onthese forward-looking statements, which speak only as of the datehereof. This caution is made under the safe harbor provisions of thePrivate Securities Litigation Reform Act of 1995. All forward-lookingstatements are qualified in their entirety by this cautionary statementand ACADIA undertakes no obligation to revise or update this pressrelease to reflect events or circumstances after the date hereof, exceptas required by law.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:
ACADIA Pharmaceuticals Inc.
LisaBarthelemy, 858-558-2871
ir@acadia-pharm.com
or
MediaContact:
Taft Communications
Bob Laverty,609-558-5570
bob@taftcommunications.com